Skip to content. | Skip to navigation

Personal tools

Rachel Fung

Research Assistant II, Immunotherapy

 Rachel Fung Lab

MSc in Cancer Sciences, University of Alberta,2017
BSc Honours, Immunology and Infection, University of Alberta, 2014
Tel: 250-519-5706

Research Interest

Immunotherapy, CAR-T therapy
Chimeric antigen receptor (CAR)-T cell therapy is a major development in the field of immunotherapy for blood cancers, where it has already seen clinical success in the treatment of acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphomas. Rachel has recently joined the DRC as a part of the immunotherapy team, with a primary interest in the development of a CD19 CAR-T therapy for clinical trials in Canada. She completed her graduate studies at the University of Alberta, where she studied the therapeutic effects of targeted radiation and oncolytic vaccinia virus on pre-clinical models of glioblastoma.